FLUAD™
influenza vaccine, adjuvanted

Introducing a flu shot for adults aged 65 years and older

FLUAD™ (influenza vaccine, adjuvanted) generates a strong immune response in adults 65+ to help protect them against the flu[1]

What is FLUAD?

- FLUAD provides at least 15 mcg of each recommended strain for the current influenza season and the proprietary adjuvant MF59® in each prefilled 0.5-mL syringe.[1]
- Studies in animals and humans suggest that MF59 recruits immune cells to the site of injection and enhances their activity.[2]
  - MF59 is derived from squalene, an oil naturally occurring in the body.[3]

INDICATIONS AND USAGE: FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in persons 65 years of age and older. Approval is based on the immune response elicited by FLUAD. Data demonstrating a decrease in influenza disease after vaccination with FLUAD are not available.[1]

CONTRAINDICATIONS: Do not administer FLUAD to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.[1]

Immunogenicity: In a large pivotal trial (N = 7082), FLUAD was shown to elicit a strong immune response vs AGRIFLU (influenza vaccine)[1,a]

Seroconversion[b] rates: FLUAD established noninferiority vs AGRIFLU at day 22[1]



	A/H1N1	A/H3N2	B
Differences in Seroconversion rate[e] (95% CI)	9.8% (7.5%-12.1%)	13.9% (11.7%-16.1%)	3.2% (1.1%-5.3%)

GMTs and GMT ratios: FLUAD established noninferiority vs AGRIFLU at day 22[1]



	A/H1N1	A/H3N2	B
GMT ratio[f] (95% CI)	1.4 (1.32-1.49)	1.61 (1.52-1.7)	1.15 (1.08-1.21)

CI = confidence interval; GMT = geometric mean antibody titer.

[a] Results obtained following vaccination with influenza vaccine formulated for the 2010-2011 season. [b] Seroconversion was defined as prevaccination HI titer <10 and postvaccination HI titer ≥ 40 or at least a 4-fold increase in HI from prevaccination HI titer ≥ 10. [c] N = 3225-3227, the number of vaccinated participants with available data for the immunologic endpoint listed. [d] N = 3256-3259, the number of vaccinated participants with available data for the immunologic endpoint listed. [e] FLUAD met noninferiority criteria based on seroconversion rate differences if the lower limit of the 95% CI [FLUAD – AGRIFLU] for each strain was >-10%. [f] FLUAD met noninferiority criteria based on GMT ratios if the lower limit of the 95% CI [FLUAD: AGRIFLU] for each strain was >0.67.

FLUAD may not be 100% effective in all who receive it.[1]

Study design: Study 1 (NCT01162122) was a multicenter, observer-blind, randomized controlled study that evaluated the safety and immunogenicity of FLUAD in comparison to AGRIFLU. A total of 7082 subjects aged 65 years and older were randomized and vaccinated with FLUAD (N = 3541) or AGRIFLU (N = 3541). The primary immunogenicity analysis was performed on all vaccinated subjects who had a blood sample collected at Day 22 (N = 3225-3227 [91%] and 3256-3259 [92%] in the FLUAD and AGRIFLU groups, respectively). A determination of noninferiority was made on the basis of predefined thresholds for seroconversion rate differences and GMT ratios. The safety analysis included subjects (N = 3545 FLUAD, 3537 AGRIFLU) from Study 1 who completed a symptom diary card for 7 days following vaccination. Additional safety data were derived from 15 randomized controlled studies involving 10,952 adults aged 65 years and older who received FLUAD (N = 5754) or other US-licensed vaccines (N = 5198).[1]

Please see Important Safety Information on opposite side and accompanying US full Prescribing Information.

FLUAD: Safety Results From the Pivotal Trial

FLUAD: Solicited Local Adverse Reactions[1]

		FLUAD N[b] = 3418-3496 %	AGRIFLU[a] N[b] = 3420-3488 %
Injection site pain	Any	25.0	12.2
	Moderate[c]	3.9	1.9
	Severe[d]	0.3	0.2
Tenderness	Any	21.1	11.2
	Moderate	3.0	1.0
	Severe	0.1	0.2
Erythema	Any	1.2	0.5
	25 to ≤50 mm	1.1	0.5
	51 to ≤100 mm	0.2	<0.1
	>100 mm	0.0	0.0
Induration	Any	1.3	0.5
	25 to ≤50 mm	1.0	0.5
	51 to ≤100 mm	0.3	0.0
	>100 mm	0.0	0.0
Swelling	Any	1.2	0.4
	25 to ≤50 mm	1.0	0.4
	51 to ≤100 mm	0.2	<0.1
	>100 mm	<0.1	0.0

[a] AGRIFLU (influenza vaccine) is a US-licensed nonadjuvanted influenza vaccine.
[b] N = number of subjects with safety data.
[c] Moderate: pain, tenderness, myalgia, fatigue, headache, arthralgia, chills, nausea, vomiting defined as "some limitation in normal daily activity," diarrhea defined as "4 to 5 stools a day."
[d] Severe: pain, tenderness, myalgia, fatigue, headache, arthralgia, chills, nausea, vomiting defined as "unable to perform normal daily activity," diarrhea defined as "6 or more watery stools a day."



FLUAD: How Supplied

- Package of ten 0.5 mL prefilled, needleless syringes per carton (NDC number: 66521-000-01)[1]

CPT Code: 90653

FLUAD: Accepted Use Worldwide

- Over 81 million doses distributed worldwide since 1997[4]
- Approved in more than 30 countries worldwide[4]

FLUAD: Solicited Systemic Adverse Reactions[1]

		FLUAD N[b] = 3418-3496 %	AGRIFLU[a] N[b] = 3420-3488 %
Myalgia	Any	14.7	9.7
	Moderate[c]	2.6	1.8
	Severe[d]	0.3	0.7
Fatigue	Any	13.3	10.4
	Moderate	3.1	2.4
	Severe	0.4	0.6
	PLT[e]	0.0	<0.1
Headache	Any	13.2	11.2
	Moderate	3.0	2.6
	Severe	0.4	0.6
	PLT	0.0	<0.1
Arthralgia	Any	8.5	7.8
	Moderate	1.6	1.6
	Severe	0.2	0.6
Chills	Any	6.7	4.7
	Moderate	1.5	1.2
	Severe	0.3	0.3
	PLT	<0.1	0.0
Diarrhea	Any	4.8	4.5
	Moderate	1.3	0.9
	Severe	0.3	0.2
	PLT	<0.1	<0.1
Fever	Any	3.6	3.4
	≥38.0°C to ≤38.4°C	1.8	1.7
	≥38.5°C to ≤38.9°C	1.3	1.3
	39.0°C to ≤40.0°C	0.4	0.4
	≥40.0°C	0.1	0.0
Nausea	Any	2.9	2.8
	Moderate	0.4	0.6
	Severe	0.1	0.1
	PLT	<0.1	0.0
Vomiting	Any	1.4	1.7
	Moderate	0.4	0.5
	Severe	<0.1	0.1
	PLT	<0.1	0.0

[a] AGRIFLU (influenza vaccine) is a US-licensed nonadjuvanted influenza vaccine.
[b] N = number of subjects with safety data.
[c] Moderate: pain, tenderness, myalgia, fatigue, headache, arthralgia, chills, nausea, vomiting defined as "some limitation in normal daily activity," diarrhea defined as "4 to 5 stools a day."
[d] Severe: pain, tenderness, myalgia, fatigue, headache, arthralgia, chills, nausea, vomiting defined as "unable to perform normal daily activity," diarrhea defined as "6 or more watery stools a day."
[e] Potentially life threatening (PLT) reaction defined as requiring emergency room visit or hospitalization.

Important Safety Information

INDICATIONS AND USAGE
FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in persons 65 years of age and older.[1]

CONTRAINDICATIONS
Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.[1]

WARNINGS AND PRECAUTIONS[1]
- If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.
- The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions in latex sensitive individuals.

ADVERSE REACTIONS[1]
- The most common (≥10%) local (injection-site) adverse reactions observed in clinical studies were injection site pain (25%) and tenderness (21%).
- The most common (≥10%) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%), and fatigue (13%).

References: 1. FLUAD [package insert]. Holly Springs, NC: Seqirus, Inc; 2015. **2.** O'Hagan D, Ott G, De Gregorio E, Seubert A. The mechanism of action of MF59® - An innately attractive adjuvant formulation. *Vaccine*. 2012;30:4341-4348. doi:10.1016/j.vaccine.2011.09.06. **3.** Squalene-based adjuvants in vaccines. http://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/. Updated 2015. Accessed June 12, 2015. **4.** Seqirus Inc. Data on file. Vaccine: V70; Fluad™; aTIV Development Safety Update Report. 2015. Accessed July 14, 2015.

Please see accompanying US full Prescribing Information.

Seqirus Inc.
Holly Springs, North Carolina 27540

February 2016 GMCC-638_2015-11-23_S

FLUAD™ influenza vaccine, adjuvanted